BioMS Medical to present clinical and manufacturing information at TIDES Conference "They will be presenting general clinical trial information on BioMS Medical's lead product, MBP8298, for the treatment of MS. MBP8298 is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (MBP). MBP8298 has been developed for the treatment of MS and BioMS is currently enrolling patients across Canada, the U.K. and Sweden in its pivotal phase II/III clinical trial evaluating MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS)..."